Dysmenorrhea

Advil Introduces Advil PLUS Acetaminophen to Canadians, Combining Two Trusted Pain Relievers into One Convenient Tablet

Retrieved on: 
Wednesday, August 3, 2022
Angus Munn, Diclofenac, Mineral, Inflammation, Human, Fever, COX, PMID, Health, Paracetamol, NSAID, Pain, MISSISSAUGA, LSE, Literature, Safety, GlaxoSmithKline, Ibuprofen, HLN, BioMed Central, Science, Dysmenorrhea, VMS, McNeil Consumer Healthcare, Central nervous system, University of Waterloo School of Pharmacy, University, Waterloo, New Zealand, Headache, Pharmaceutical industry, Dietary supplement, Centrum, Denture cleaner, Vitamin, Sensodyne, Pharmacy

New Advil PLUS Acetaminophen from Haleon (formerly GSK Consumer Healthcare), a leader in pain relief combines ibuprofen and acetaminophen to fight pain in two ways.

Key Points: 
  • New Advil PLUS Acetaminophen from Haleon (formerly GSK Consumer Healthcare), a leader in pain relief combines ibuprofen and acetaminophen to fight pain in two ways.
  • Advil PLUS Acetaminophen combines two of the most popular multi-indication pain relievers in Canada, into one convenient tablet, to help treat headaches, migraine pain, back, muscle, joint, menstrual pain and fever.
  • Advil PLUS Acetaminophen is indicated for fast and effective temporary pain relief in adults over 18 years.
  • Before using the product, consumers should read the Advil PLUS Acetaminophen drug facts label and consumer medication leaflet.

Myovant Sciences and Pfizer Announce Publication in The Lancet of Phase 3 SPIRIT 1 and SPIRIT 2 Studies of Once-Daily Relugolix Combination Therapy in Women With Endometriosis-Associated Pain

Retrieved on: 
Friday, June 17, 2022
Pfizer, Roivant Sciences, Endometriosis, Dysmenorrhea, Week, GLOBE, Pain, NEW, SPIRIT, Dyspareunia, NYSE, Norethisterone, Woman, PFE, Pharmaceutical industry, Birth control, Medical imaging, Lancet

In both studies, relugolix combination therapy was associated with a generally well-tolerated safety profile, including bone mineral density loss of

Key Points: 
  • In both studies, relugolix combination therapy was associated with a generally well-tolerated safety profile, including bone mineral density loss of
  • Seven key secondary endpoints in SPIRIT 1 and six key secondary endpoints in SPIRIT 2 comparing relugolix combination therapy with placebo at Week 24 also achieved statistical significance.
  • The most frequently reported adverse events in both relugolix combination treatment and placebo groups were headache, nasopharyngitis, and hot flushes.
  • For endometriosis-associated pain, current treatment options include prescription and over-the-counter pain medications, oral contraceptives, GnRH agonists, and antagonists.

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix at Multiple Congresses

Retrieved on: 
Wednesday, May 25, 2022
International Society, Catholic higher education, HMB, Gynecological Endocrinology, EDELWEISS, Uterine fibroid, Catholic University of Leuven (1834–1968), Doctor of Philosophy, World Congress, PRIMROSE, NASDAQ, LGX, Constipation, Gonadotropin-releasing hormone, Treatment, DYS, Uterus, MBL, Congress, Yale School of Medicine, Safety, Dysmenorrhea, ABT, Pharmaceutical industry, Birth control, Medical imaging, Endometriosis, Woman, MD

GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.

Key Points: 
  • GENEVA, Switzerland May 25, 2022 ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for womens health, today announced the presentation of clinical data on linzagolix, an oral GnRH antagonist.
  • The encouraging data presented at these important medical congresses highlight the differentiated therapeutic potential of linzagolix to better address the individual needs of women with uterine fibroids and endometriosis, said Dr. Brandi Howard, Chief Clinical Officer of ObsEva.
  • These data demonstrate that linzagolix with or without add-back therapy (ABT) significantly reduced heavy menstrual bleeding due to uterine fibroids.
  • Linzagolix is an investigational novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile1,2,3.

Research Shows Pycnogenol® French Maritime Pine Bark Extract Is a Key Natural Supplement to Support Women's Health Throughout Life

Retrieved on: 
Wednesday, May 11, 2022
Menopause, National Women's Health Network, Urinary tract infection, Woman, Collagen, Dysmenorrhea, Safety, Research, Cognition, Dietary supplement, Patient, Infection, Frost, Blood, Review, Malcolm Baldrige National Quality Award, Risk, Overalls, Anxiety, Dyssomnia, Skin, Homocysteine, Health, Nervous, Science, Memory, Joint, Life, Goal, Hyaluronic acid, Multimedia, Birth control, Condensed tannin

HOBOKEN, N.J., May 11, 2022 /PRNewswire/ -- Women's health goals and concerns evolve and change with age. In observance of National Women's Health Month during May, experts are highlighting Pycnogenol® French maritime pine bark extract as a leading supplement for women's health throughout life. The super antioxidant is supported by a vast catalog of research demonstrating its widespread benefits for supporting skin, cognitive and joint health and managing menstrual pain, UTIs and menopause.

Key Points: 
  • In observance of National Women's Health Month during May, experts are highlighting Pycnogenol French maritime pine bark extract as a leading supplement for women's health throughout life.
  • "Women's Health Month is a time for women to make their health and well-being a top priority.
  • Pycnogenol French maritime pine bark extract is a proven, unique, standardized blend of powerful natural antioxidants.
  • Horphag Research is the exclusive worldwide distributor for Pycnogenol (pic-noj-en-all) brand French maritime pine bark extract.

ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Tuesday, March 22, 2022
EAP, Private Securities Litigation Reform Act, Menstrual cycle, Drug development, Nephrology Dialysis Transplantation, Risk, Norethisterone, Dyspareunia, Investor, Analgesic, SIX Swiss Exchange, Ovulation, EDELWEISS, Fertility, Clinical trial, Infertility, Birth certificate, Coronavirus, Uterine fibroid, Constipation, Urology, Pelvic pain, SEC, Pregnancy, Uterus, Research, Woman, Endometrium, Patient, CEO, Gonadotropin-releasing hormone, Pain, Gynaecology, Security (finance), Sexual intercourse, Safety, Defecation, ABT, Estradiol, U.S. Securities and Exchange Commission, Dysmenorrhea, Endometriosis, Nasdaq, Linzagolix, Fatigue, Disease, Pharmaceutical industry, Birth control, Kissei

EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.

Key Points: 
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.
  • Results from the post-treatment follow-up of EDELWEISS 3 are expected in early 3Q2022.
  • Results from the treatment phase of the extension study (EDELWEISS 6) and its post-treatment follow-up phase are expected in early 3Q2022 and 4Q2022, respectively.

ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Tuesday, March 22, 2022
EAP, Private Securities Litigation Reform Act, Menstrual cycle, Drug development, Nephrology Dialysis Transplantation, Risk, Norethisterone, Dyspareunia, Investor, Analgesic, SIX Swiss Exchange, Ovulation, EDELWEISS, Fertility, Clinical trial, Infertility, Birth certificate, Coronavirus, Uterine fibroid, Constipation, Urology, Pelvic pain, SEC, Pregnancy, Uterus, Research, Woman, Endometrium, Patient, CEO, Gonadotropin-releasing hormone, Pain, Gynaecology, Security (finance), Sexual intercourse, Safety, Defecation, ABT, Estradiol, U.S. Securities and Exchange Commission, Dysmenorrhea, Endometriosis, Nasdaq, Linzagolix, Fatigue, Disease, Pharmaceutical industry, Birth control, Kissei

EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.

Key Points: 
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.
  • Results from the post-treatment follow-up of EDELWEISS 3 are expected in early 3Q2022.
  • Results from the treatment phase of the extension study (EDELWEISS 6) and its post-treatment follow-up phase are expected in early 3Q2022 and 4Q2022, respectively.

Endometriosis Epidemiology Forecast Report 2021-2030 - Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 15, 2022
Health, General Health, Epidemiology, Doctor of Philosophy, Phenotype, Minimal, Laparoscopy, Pain scale, OMA, Risk, ASRM, DIE, Moderate, Woman, CPP, AGR, Dysmenorrhea, SUP, Dyspareunia, Rollcage Stage II, Renewable energy, Dietary supplement, Vaccine, Management, Endometriosis

The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis.

Key Points: 
  • The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis.
  • The diagnosed prevalent cases of endometriosis are segmented by age (12-54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis).
  • The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of endometriosis.
  • The diagnosed prevalent cases of endometriosis are segmented by age (12-54 years) and laparoscopy confirmation status (whether suspected or confirmed endometriosis).

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Thursday, January 6, 2022
ID, EMA, Clinical trial, Endometriosis, Safety, Pelvic pain, Pregnancy, Urology, Uterine fibroid, Estradiol, Endometrium, Menstrual cycle, Sexual intercourse, Birth certificate, Investor, SIX Swiss Exchange, Patient, Uterus, Fertility, Dysmenorrhea, Nephrology Dialysis Transplantation, Gonadotropin-releasing hormone, Analgesic, BMD, Security (finance), Report, Risk, Private Securities Litigation Reform Act, Gynaecology, Central European Time, Disease, CEO, EAP, SEC, Norethisterone, Research, FDA, EDELWEISS, Woman, Infertility, Pain, Defecation, ABT, Dyspareunia, U.S. Securities and Exchange Commission, Drug development, Constipation, Headache, Linzagolix, Fatigue, Nasdaq, Coronavirus, Ovulation, Pharmaceutical industry, Birth control, Kissei

ObsEva will host a conference call and audio webcast with Dr. Hugh Taylor today, January 6 at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to discuss Phase 3 EDELWEISS 3 trial results of linzagolix.

Key Points: 
  • ObsEva will host a conference call and audio webcast with Dr. Hugh Taylor today, January 6 at 8:00 a.m. Eastern Time/2:00 p.m. Central European Time to discuss Phase 3 EDELWEISS 3 trial results of linzagolix.
  • Investors may participate by dialing 1-877-407-9208 for U.S. callers or +1-201-493-6784 for international callers and refer to conference ID 13725902.
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.

ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

Retrieved on: 
Thursday, January 6, 2022
ID, EMA, Clinical trial, Endometriosis, Safety, Pelvic pain, Pregnancy, Urology, Uterine fibroid, Estradiol, Endometrium, Menstrual cycle, Sexual intercourse, Birth certificate, Investor, SIX Swiss Exchange, Patient, Uterus, Fertility, Dysmenorrhea, Nephrology Dialysis Transplantation, Gonadotropin-releasing hormone, Analgesic, BMD, Security (finance), Report, Risk, Private Securities Litigation Reform Act, Gynaecology, Central European Time, Disease, CEO, EAP, SEC, Norethisterone, Research, FDA, EDELWEISS, Woman, Infertility, Pain, Defecation, ABT, Dyspareunia, U.S. Securities and Exchange Commission, Drug development, Constipation, Headache, Linzagolix, Fatigue, Nasdaq, Coronavirus, Ovulation, Pharmaceutical industry, Birth control, Kissei

We remain dedicated to providing flexible treatment options for women and look forward to further development of linzagolix in the endometriosis indication.

Key Points: 
  • We remain dedicated to providing flexible treatment options for women and look forward to further development of linzagolix in the endometriosis indication.
  • Investors may participate by dialing 1-877-407-9208 for U.S. callers or +1-201-493-6784 for international callers and refer to conference ID 13725902.
  • EDELWEISS 3 (Europe and the U.S.) was a randomized, double-blind, placebo-controlled, Phase 3 trial that analyzed 484 women with moderate-to-severe EAP.
  • The study included a 200 mg once-daily dose in combination with ABT (1 mg estradiol / 0.5 mg norethindrone acetate), and a 75 mg once-daily dose without ABT.

Claritas Outlines Development Strategy for R-107 for Multiple Diseases, Disorders and Injuries

Retrieved on: 
Tuesday, January 4, 2022
COVID-19, Scientific Reports, Disorder, Burn, Injury, Mortality, PAH, Human services, Sepsis, Ino, ECMO, Sexual dysfunction, CEO, OTC, USD, Acute respiratory distress syndrome, Dressing (medical), Burns, Pulmonary hypertension, Royal Brompton Hospital, Wound healing, Respiratory distress syndrome, Dysmenorrhea, Trial of the century, Report, PPHN, RDS, CLAS, Death, CA, Human, Nitric oxide, SAN, GLOBE, Female, Anal fissure, Office of Inspector General, U.S. Department of Health and Human Services, Science, COVID, Degenerative disease, Disease, Â, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Solution, Therapy, Patient, Standards for Reporting Enzymology Data, TSX, Mouth, Pharmaceutical industry, Times New Roman

Claritas is poised to accelerate development of R-107 for treatment of numerous diseases, disorders and injuries, stated Robert Farrell, Claritas President and CEO.

Key Points: 
  • Claritas is poised to accelerate development of R-107 for treatment of numerous diseases, disorders and injuries, stated Robert Farrell, Claritas President and CEO.
  • Our development strategy is straightforward, as follows:
    Phase 1 Study in Q1 2022: The first step is completion of our Phase 1 clinical study to demonstrate that R-107 is safe in humans.
  • Depending on how it is administered, R-107 can target multiple diseases, disorders, and injuries.
  • Claritas Pharmaceuticals, Inc. ("Claritas") is committed to developing new treatments for a variety of diseases and disorders, by discovering, developing, manufacturing, and delivering innovative human therapeutics.